PF-06650833
- Generic Name
- PF-06650833
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H20FN3O4
- CAS Number
- 1817626-54-2
- Unique Ingredient Identifier
- S3F315JJXI
- Background
PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT05064332
- Locations
- πΊπΈ
Qps-Mra, Llc, South Miami, Florida, United States
IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Giovanni Franchin, M.D, Ph.D
- Target Recruit Count
- 68
- Registration Number
- NCT04933799
- Locations
- πΊπΈ
Bronx-Lebanon Hospital Center Health Care System, Bronx, New York, United States
IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Yale University
- Target Recruit Count
- 7
- Registration Number
- NCT04575610
- Locations
- πΊπΈ
Yale New Haven Hospital, New Haven, Connecticut, United States
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 460
- Registration Number
- NCT04413617
- Locations
- π§π¬
Independent Medical Diagnostic Laboratory Mediscan EOOD, Plovdiv, Bulgaria
π§π¬MHAT Plovdiv AD, Plovdiv, Bulgaria
π§π¬DCC Sveti Georgi EOOD, Plovdiv, Bulgaria
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 194
- Registration Number
- NCT04092452
- Locations
- πΊπΈ
Boston Medical Center, Boston, Massachusetts, United States
πΊπΈDermatology Associates of Seattle, Seattle, Washington, United States
πΊπΈDawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT03308110
- Locations
- π§πͺ
Pfizer Clinical Research Unit, Brussels, Belgium
Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 269
- Registration Number
- NCT02996500
- Locations
- πΊπΈ
Arthritis & Rheumatic Care Center, South Miami, Florida, United States
πΊπΈMedical Associates of North Georgia, Canton, Georgia, United States
πΊπΈMillennium Research, Ormond Beach, Florida, United States
Study for MR Formulation of PF-06650833 in Healthy Adult Japanese Subjects
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT02936154
- Locations
- π―π΅
P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan
Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT02609139
- Locations
- πΊπΈ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 71
- Registration Number
- NCT02485769
- Locations
- πΊπΈ
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.